Here's Why You Should Invest in Boston Scientific (BSX) Now

Boston Scientific Corporation BSX is gaining from consistent growth in the legacy business across several geographies, even amid macroeconomic issues. The next generation WATCHMAN FLX is capturing the European market. Acquisitions, too are contributing to the topline. The increased 2023 guidance indicates that the company is well-poised to handle the industry-wise trend of currency headwinds and global inflationary pressure. However, unfavorable currency movements and stiff competition are a concern.

In the past year, this Zacks Rank #3 (Hold) stock has gained 35.9% compared with the 0.2% fall of the industry and a 22.2% rise of the S&P 500.

The renowned manufacturer of medical devices and products has a market capitalization of $78.78 billion. The company’s long-term projected growth of 12.8% compares with the industry’s growth projection of 13.8%.

Let’s delve deeper.

Factors At Play

Geographic Expansion Continues: Boston Scientific successfully expands operations across different geographies outside the United States. In 2022, 40% of the company’s consolidated revenues came from international regions.
In the second quarter, EMEA sales grew 9% year over year on an operational basis, with double-digit growth in four of the company’s five major markets in Europe. Across the portfolio, Boston Scientific saw strength in new and ongoing product launches, including FARAPULSE, POLARx, ACURATE neo2 and LUX-DX. The company remains excited about the year ahead and expects to continue to outpace its peers within the EMEA market.

WATCHMAN, a Long-Term Growth Component: Boston Scientific’s structural heart programs are fast building momentum, banking on the solid performance of the WATCHMAN left atrial appendage closure device. WATCHMAN is the first device to offer a non-pharmacologic alternative to oral anti-coagulants that has been studied in a randomized clinical trial and is the leading device in percutaneous LAAC globally. The next generation WATCHMAN FLX is strongly capturing the European market.

Zacks Investment ResearchImage Source: Zacks Investment Research

In the second quarter of 2023, Boston Scientific noted that WATCHMAN’s organic sales grew 27% year over year. The U.S. demand remained strong and international growth was led by China and Japan. Our estimate suggests an 8.3% improvement in the company's Watchman revenue in 2023.

Upbeat Guidance: Boston Scientific’s full-year net sales growth is expected in the range of 10.5-11.5% on a reported basis (earlier estimate was 8.5-10.5% growth). Net sales growth is expected to be in the range of 10-11% on an organic basis (8-10%).

Full-year adjusted earnings per share is expected to be $1.96 to $2.00 ($1.90 to $1.96). The Zacks Consensus Estimate is currently pegged at $1.95, below the guidance.

For the third quarter of 2023, revenue growth is projected in the range of approximately 8.5-10.5% on a reported basis (an increase of 7-9% organically).
Adjusted earnings are expected to be 46-48 cents per share.

Downsides

Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a significant dampener over the last few quarters, as with other important MedTech players.

Competitive Landscape: The presence of many players has made the medical devices market highly competitive. The company participates in several markets, including Cardiovascular, CRM, Endosurgery and Neuromodulation, where it faces competition from large, well-capitalized companies such as Johnson & Johnson, Abbott, Medtronic, Stryker, Smith & Nephew and Edwards Lifesciences, apart from several other smaller companies.

Estimate Trend

The Zacks Consensus Estimate for Boston Scientific’s 2023 earnings is pegged at $1.99 per share, indicating a 16.4% increase from the 2022 reported number.

The Zacks Consensus Estimate for 2023 revenues is pegged at $14.07 billion, suggesting a 10.9% rise from the 2022 figure.

Key Picks

Some other top-ranked stocks in the broader medical space are DaVita Inc. DVA, Quanterix QTRX and Align Technology ALGN, each carrying a Zacks Rank #2.

DaVita has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DaVita has gained 25.5% against the industry’s 8.9% decline in the past year.

Estimates for Quanterix’s 2023 loss per share have remained constant at 97 cents in the past 30 days. Shares of the company have surged 141.5% in the past year compared with the industry’s fall of 5.6%.

QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.

Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have increased 27% in the past year compared with the industry’s rise of 14.3%.

ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it posted an earnings surprise of 9.90%.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

DaVita Inc. (DVA) : Free Stock Analysis Report

Align Technology, Inc. (ALGN) : Free Stock Analysis Report

Quanterix Corporation (QTRX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.